Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 5/20 | 0.38 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | TACR2 | P21452 | 2/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6668093 | 0.90 | KMT2A (0.41) | KMT2ACNR1TACR1TACR2 | |
| SCHEMBL3980986 | 0.90 | CNR1 (0.37) | KMT2ACNR1TACR1TACR2OPRD1 | |
| SCHEMBL3980984 | 0.90 | CNR1 (0.37) | KMT2ACNR1TACR1TACR2OPRD1 | |
| SCHEMBL3987361 | 0.90 | CNR1 (0.39) | KMT2ACNR1TACR1TACR2 | |
| SCHEMBL3979436 | 0.90 | CNR1 (0.39) | KMT2ACNR1OPRD1OPRK1 | |
| SCHEMBL3987362 | 0.90 | CNR1 (0.39) | KMT2ACNR1TACR1TACR2 | |
| SCHEMBL3983091 | 0.90 | CNR1 (0.39) | KMT2ACNR1OPRD1OPRK1 | |
| SCHEMBL4870849 | 0.89 | TACR2 (0.38) | TACR1TACR2 | |
| SCHEMBL5106738 | 0.89 | TACR2 (0.38) | TACR1TACR2 | |
| SCHEMBL6664233 | 0.89 | KMT2A (0.41) | KMT2ATACR1TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1165528-B1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI SYNTHELABO (FR) | 2004-09-01 | — | — | EP | disclosed |
| US-6506750-B1 | N-(phenylacetyl)morpholine derivatives useful as NK1 receptor antagonists, a process for the preparation thereof, and pharmaceutical compositions containing them as active principle. | SANOFI-SYNTHELABO (FR) | 2003-01-14 | — | — | US | disclosed |
| EP-1165528-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000058292-A1 | NOVEL MORPHOLINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID DERIVATIVES | SANOFI-SYNTHELABO (FR) | 2000-10-05 | — | — | WO | disclosed |